Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models

Cancer Research

Volumn 59, Issue 23, 1999, Pages 5896-5901

  Nielsen, Loretta L ^a   Shi, Bin ^a   Hajian, Gerald ^a   Yaremko, Bohden ^a   Lipari, Philip ^a   Ferrari, Eric ^a   Gurnani, Maya ^a   Malkowski, Michael ^a   Chen, Jiaping ^a   Bishop, W Robert ^a   Liu, Ming ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LONAFARNIB; P53 ADENOVIRUS; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CANCER THERAPY; CELL PROLIFERATION; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL MODEL;

ADENOCARCINOMA; ADENOVIRUSES, HUMAN; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; GENES, RAS; HUMANS; MALE; MICE; MICE, NUDE; MICE, SCID; MICE, TRANSGENIC; OVARIAN NEOPLASMS; PACLITAXEL; PANCREATIC NEOPLASMS; PIPERIDINES; PROSTATIC NEOPLASMS; PYRIDINES; TERATOCARCINOMA; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033407426     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Barbacid, M. Ras genes. Annu. Rev. Biochem., 56: 779-827, 1987.
2. Joneson, T., White, M. A., Wigler, M. H., and Bar-Sagi, D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science (Washington DC), 271: 810-811, 1996.
3. Lowy, D. R., and Willumsen, B. M. Function and regulation of Ras. Annu. Rev. Biochem., 62: 851-891, 1993.
4. Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
5. Gibbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell, 77: 175-178, 1994.
6. Gibbs, J. B., Kohl, N. E., Koblan, K. S., Omer, C. A., Sepp-Lorenzino, L., Rosen, N., Anthony, N. J., Conner, M. W., deSolms, S. J., Williams, T. M., Graham, S. L., Hartman, G. D., and Oliff, A. Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res. Treat., 38: 75-83, 1996.
7. Plattner, R., Anderson, M. J., Sato, K. Y., Fasching, C. L., Der, C. J., and Stanbridge, E. J. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc. Natl. Acad. Sci. USA, 93: 6665-6670, 1996.
8. Shirasawa, S., Furuse, M., Yokoyama, N., and Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (Washington DC), 260: 85-88, 1993.
9. Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., and Der, C. J. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA, 87: 3042-3046, 1990.
10. Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., and Der. C. J. lsoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA, 89: 6403-6407, 1992.
11. Schaefer, W. R., Kim, R., Sterne, R., Thorner, J., Kim, S-H., and Rine, J. Genetic and pharmacological suppression of oncogenic mutations in RAS genes of yeast and humans. Science (Washington DC), 245: 379-385, 1989.
12. James, G. L., Goldstein, J. L., and Brown, M. S. Polylysine, and CV1M sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem., 270: 6221-6226, 1995.
13. Zhang, F., Bond, R., Wang, L., Windsor, W., Kirschmeier, P., Carr, D., and Bishop, W. R. Characterization of H, K and N-Ras as in vitro substrates for isoprenyl protein transferases. J. Biol. Chem., 272: 10232-10239, 1997.
14. Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., and Garcia, A. M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem., 272: 14093-14097, 1997.
15. Whyte, D. B., Kirschmeir, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Cantino, J. J., Bishop, W. R., and Pai, J-K. K-, and N-Ras are geranylgeranylated in cells treated with famesyl protein transferase inhibitors. J. Biol. Chem., 272: 14459-14464, 1997.
16. Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., DeSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., Lee, T-J., Smith, R. L., Graham, S. L., Hartman, G. D., Gibbs, J. B., and Oliff, A. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA, 91: 9141-9145, 1994.
17. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., DeSolms, S. J., Giuliani, E., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartman, G. D., Koblan, K. S., Kral, A. M., Miller, P. J., Mosser, S. D., O'Neill, T. J., Rands, E., Schaber, M. D., Gibbs, J. B., and Oliff, A. Inhibition of famesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
18. Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Li, Z., Dell, J., Lipari, P., Malkowski, M., Prioli, N., Rossman, R. R., Korfmacher, W. A., Nomeir, A. A., Lin, C-D., Mallams, A. K., Kirschmeier, P., Doll, R. J., Catino, J. J., Girijavallabhan, V. M., and Bishop, W. R. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice. Cancer Chemother. Pharmacol., 43: 50-58, 1999.
19. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res., 55: 5310-5314, 1995.
20. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res., 55: 4243-4247, 1995.
21. Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M., Ferrari, E., Nielsen, L., Prioli, N., Dell, J., Sinha, D., Syed, J., Korfmacher, W. A., Nomeir, A. A., Lin, C. C., Wang, L., Taveras, A. G., Doll, R. J., Njoroge, G. F., Mallams, A. K., Remiszewski, S., Catino, J. J., Girijavallabhan, V. M., Kirschmeier, P., and Bishop, W. R. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models, and wap-ras transgenic mice. Cancer Res., 58: 4947-4956, 1998.
22. Njoroge, F. G., Vibulbhan, B., Pinto, P., Bishop, W. R., Brayant, M. S., Nomeir, A. A., Lin, C-C., Liu, M., Doll, F. J., Girijavallabhan, V., and Ganguly, A. K. Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity. J. Med. Chem., 41: 1561-1567, 1998.
23. Ozbun, M. A., and Butel, J. S. Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv. Cancer Res., 66: 71-141, 1995.
24. Seller, H., and Montenarh, M. The emerging picture of p53. Int. J Biochem., 26: 145-154, 1994.
25. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
26. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
27. Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M-T., Huang, W-M., Johnson, D. E., Anderson, S. C., Wen, S. F., Bookstein, R., Shepard, H. M., and Gregory, R. J. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther., 5: 1079-1088, 1994.
28. Anderson, S. C., Johnson, D. E., Harris, M. P., Engler, H., Hancock, W., Huang, W., Wills, KN, Gregory, R. J., Sutjipto, S., Wen, S. F., Lofgren, S., Shepard, H. M., and Maneval, D. C. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin. Cancer Res., 4: 1649-1659, 1998.
29. Gurnani, M., Lipari, P., Dell, J., Shi, B., and Nielsen, L. L. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother. Pharmacol., 44: 143-151, 1999.
30. Nielsen, L. L., and Maneval, D. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther., 5: 52-63, 1998.
31. Nielsen, L. L., Gurnani, M., Syed, J., Dell, J., Hartman, B., Cartwright, M., and Johnson, R. C. Recombinant El-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in mouse tumor xenograft models. Human Gene Ther., 9: 681-694, 1998.
32. Nielsen, L. L., Lipari, P., Dell, J., Gurnani, M., and Hajian, G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res., 4: 835-846, 1998.
33. Horwitz, S. B. Mechanism of action of taxol. Trends Pharmacol. Sci., 13: 134-136, 1992.
34. Rowinsky, E. K., Cazenave, L. A., and Donehower, R. C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst., 82: 1247-1259, 1990.
35. Donaldson, K. L., Goolsby, G. L., and Wahl, A. F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer, 57: 847-855, 1994.
36. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W., and Galloway, D. A. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
37. Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff, A., Balog, A., Su, D., Danishefsky, S. J., and Rosen, N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA, 95: 1369-1374, 1998.
38. Huyghe, B. G., Liu, X., Sutjipto, S., Sugarman, B. J., Horn, M. T., Shepard, H. M., Scandella, C. J., and Shabram, P. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther., 6: 1403-1416, 1995.
39. Musco, M. L., Cui, S., Small, D., Nodelman, M., Sugarman, B., and Grace, M. A comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenoviral infectivity and p53 protein expression in gene therapy. Cytometry, 33: 290-296, 1998.
40. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 64: 55-63, 1983.
41. O'Connell, M. A., and Wolfinger, R. D. Spatial regression models, response surfaces, and process optimization. J. Comput. Graph. Stat., 6: 224-241, 1997.
42. Nielsen, L. L., Gurnani, M., and Tyler, R. D. Evaluation of the wap-ras transgenic mouse as a model system for testing anti-cancer drugs. Cancer Res., 52: 3733-3738, 1992.
43. Nielsen, L. L., Gurnani, M., Catino, J., and Tyler, R. D. In wap-ras transgenic mice, tumor phenotype, but not cyclophosphamide-sensitivity is affected by genetic background. Anticancer Res., 15: 385-392, 1995.
44. Porter, G., Armstrong, L., and Nielsen, L. L. A strategy for developing transgenic assays for screening anti-neoplastic drugs which affect tubulin polymerization. Lab. Anim. Sci., 45: 145-150, 1995.
45. Lebowitz, P. F., Sakamuro, D., and Prendergast, G. C. Farnesyl transferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachment. Cancer Res., 57: 708-713, 1997.
46. Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A.. Bearss, D. J., Conner, M. W., Gibbs, J. B., Hamilton, K., Koblan, K. S., Mosser, S. D., O'Neill, T. J., Schaber, M. D., Senderak, E. T., Windle, J. J., Oliff, A., and Kohl, N. E. A farnesyl transferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol., 18: 85-92, 1998.
47. Cox, A. D., and Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply ras? Biochim. Biophys. Acta, 1333: F51-F71, 1997.
48. Sepp-Lorenzino, L., and Rosen, N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild-type tumor cells. J. Biol. Chem., 273: 20243-20251, 1998.